First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
Innate Pharma reports first half 2020 financial results and business update
U.S. Food and Drug Administration lifts partial clinical hold on lacutamab TELLOMAK trial in advanced T-cell lymphomas
Innate Pharma to present new efficacy data for monalizumab in combination with cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program
First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors
French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sezary syndrome and mycosis fungoides
Innate Pharma provides update from regulatory agencies on lacutamab TELLOMAK trial
The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting
